Management of acute withdrawal from 7-hydroxymitragynine after high-dose chronic use: A case report

This study aimed to report acute opioid withdrawal after an abrupt cessation of high-dose 7-hydroxymitragynine (7-OH) in a patient who transitioned from kratom and to outline pharmacist-focused assessment, management, and regulatory counseling strategies including a formal causality assessment.

A 43-year-old male with opioid use disorder presented with nausea, diarrhea, abdominal cramping, restlessness, chills/clamminess, and anxiety after discontinuing concentrated 7-OH (360 mg/d, last 30 mg dose ∼ 48 hours earlier). Vital signs were blood pressure of 138/93 mm Hg, temperature of 37.7°C, heart rate of 84 beats/min, respiratory rate of 16 breaths/min, and pupils of 2-3 mm, with a clinical opioid withdrawal scale score of 5. He had transitioned from kratom to 7-OH approximately 18 months earlier. He met the DSM-V criteria for moderate opiate use disorder, although he never engaged in formal treatment. The patient reported that he transitioned from kratom to concentrated 7-OH products because he perceived stronger, faster opioid-like effects and required smaller quantities to avoid withdrawal. Emergency department management included sublingual buprenorphine-naloxone 4-1 mg, adjuncts (clonidine, ondansetron, loperamide, methocarbamol, nonsteroidal anti-inflammatory drugs, acetaminophen), counseling on precipitated withdrawal, and referral for treatment. A Naranjo assessment supported probable causality (score 6).

Concentrated 7-OH products differ from kratom leaf and can produce dependence and withdrawal; pharmacists should screen for these products, time buprenorphine initiation to moderate withdrawal, provide harm-reduction counseling, and incorporate evolving state regulations into patient education.